Jyong Biotech (NASDAQ:MENS – Get Free Report) released its earnings results on Friday. The company reported ($0.02) earnings per share for the quarter, FiscalAI reports.
Jyong Biotech Stock Down 3.4%
Shares of NASDAQ MENS traded down $0.07 during midday trading on Friday, reaching $2.01. 55,197 shares of the stock were exchanged, compared to its average volume of 68,867. Jyong Biotech has a twelve month low of $1.43 and a twelve month high of $67.00. The company has a 50 day simple moving average of $2.21 and a 200 day simple moving average of $10.63.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.
Hedge Funds Weigh In On Jyong Biotech
Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new stake in Jyong Biotech in the 3rd quarter valued at about $67,000. Geode Capital Management LLC increased its stake in Jyong Biotech by 19.6% during the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after buying an additional 10,538 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Jyong Biotech in the fourth quarter worth $49,000. Millennium Management LLC acquired a new stake in shares of Jyong Biotech in the third quarter valued at $512,000. Finally, Man Group plc acquired a new position in shares of Jyong Biotech during the fourth quarter worth about $56,000.
About Jyong Biotech
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
See Also
- Five stocks we like better than Jyong Biotech
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
Receive News & Ratings for Jyong Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jyong Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
